Compare BLTE & WH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | WH |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.4B |
| IPO Year | 2021 | 2017 |
| Metric | BLTE | WH |
|---|---|---|
| Price | $173.05 | $69.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $198.00 | $94.10 |
| AVG Volume (30 Days) | 198.1K | ★ 1.0M |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.04% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.16 |
| Revenue | N/A | ★ $1,429,000,000.00 |
| Revenue This Year | N/A | $6.86 |
| Revenue Next Year | $492.11 | $5.83 |
| P/E Ratio | ★ N/A | $32.31 |
| Revenue Growth | N/A | ★ 1.49 |
| 52 Week Low | $65.00 | $68.54 |
| 52 Week High | $200.00 | $90.35 |
| Indicator | BLTE | WH |
|---|---|---|
| Relative Strength Index (RSI) | 54.90 | 31.74 |
| Support Level | $167.80 | N/A |
| Resistance Level | $182.61 | $78.18 |
| Average True Range (ATR) | 7.90 | 1.96 |
| MACD | 2.18 | -0.47 |
| Stochastic Oscillator | 48.43 | 3.83 |
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
As of Dec. 31, 2025, Wyndham Hotels & Resorts operates 869,000 rooms across more than 20 brands predominantly in the economy and midscale segments. Ramada is the largest brand, representing around 14% of all rooms, with Days Inn (13%) and Super 8 (10%) the next two largest brands, as of the end of 2025. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represented 58% of total rooms in 2025.